Patents Assigned to ONO Pharmaceutical Co., Ltd.
  • Patent number: 11897885
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: February 13, 2024
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Publication number: 20240010658
    Abstract: A drug is provided, which containing, as an active ingredient, a compound having ABHD6 inhibitory activity in prevention and/or treatment of a disease associated with ABHD6. A compound of formula (I-A) or a pharmaceutically acceptable salt thereof has ABHD6 inhibitory activity and therefore is useful as a pharmaceutical ingredient having potent ABHD6 inhibitory activity in the prevention and/or treatment of a disease associated with ABHD6: in which all symbols represent the same meaning as the symbols described in the specification.
    Type: Application
    Filed: September 22, 2023
    Publication date: January 11, 2024
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi YOSHIDA, Ryuichi HYAKUTAKE, Nozomu NAGASHIMA, Ryosuke MISU, Shohei MORI
  • Publication number: 20240002531
    Abstract: An antibody that binds to HER2 expressed on a cancer cell or a fragment of the HER2, or an antigen binding fragment thereof are disclosed. Uses of the antibody or antigen binding fragment thereof are disclosed. The antibody or antigen binding fragment thereof is useful to target a HER2 expressing cancer cells. A-pharmaceutical composition containing the antibody or antigen binding fragment thereof is also disclosed.
    Type: Application
    Filed: November 29, 2021
    Publication date: January 4, 2024
    Applicants: ONO PHARMACEUTICAL CO., LTD., TOHOKU UNIVERSITY
    Inventors: Yukinari KATO, Mika KANEKO, Daisuke NAKAYAMA, Masayuki KUROGI
  • Patent number: 11851428
    Abstract: Disclosed is a compound of formula (I): wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: December 26, 2023
    Assignees: ONO PHARMACEUTICAL CO., LTD., VANDERBILT UNIVERSITY
    Inventors: Craig W. Lindsley, Joshua M. Wieting, Kevin M. Mcgowan, Jerod S. Denton, Kentaro Yashiro, Haruto Kurata, Yoko Sekioka, Takahiro Mori, Yuzo Iwaki
  • Publication number: 20230390303
    Abstract: The object of the present invention is to provide an effective method for treating cancer. Provided is a method for treating cancer including a combination of a standard therapy, an EP4 antagonist and an immune checkpoint inhibitor (for example, an anti-PD-1 antibody). The therapeutic method of the present invention is useful for cancer treatment.
    Type: Application
    Filed: November 12, 2021
    Publication date: December 7, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventor: Maki KONDO
  • Patent number: 11826363
    Abstract: A therapeutic agent for treatment of solid cancers, including, as an effective component, N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt in combination with osimertinib or a pharmaceutically acceptable salt thereof. The combination of the present invention has strong antitumor effect and is therefore useful for treatment of solid cancers.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: November 28, 2023
    Assignees: ONO PHARMACEUTICAL CO., LTD., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Koichi Takayama, Tadaaki Yamada, Tomoko Yasuhiro, Kohei Tanaka
  • Publication number: 20230339992
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Application
    Filed: June 22, 2023
    Publication date: October 26, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
  • Publication number: 20230310376
    Abstract: A prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis is disclosed. The prophylactic and/or therapeutic agent for idiopathic interstitial pneumonia (IPF or the like) contains a compound having an LPA3 agonistic activity or a salt thereof.
    Type: Application
    Filed: August 25, 2021
    Publication date: October 5, 2023
    Applicants: ONO PHARMACEUTICAL CO., LTD.,, TOHOKU UNIVERSITY
    Inventors: Junken AOKI, Kuniyuki KANO, Yasuaki HASHIMOTO, Michiaki KADODE, Yuji KAWAHARA
  • Publication number: 20230277546
    Abstract: A suppression of postsurgical recurrence and/or metastasis of cancer by administering a beta-blocker to a cancer patient during a perioperative period of cancer surgery is disclosed. Accordingly, the disclosure provides an agent for suppressing recurrence and/or metastasis of cancer, containing a beta-blocker and being administered during a perioperative period of cancer surgery.
    Type: Application
    Filed: December 30, 2022
    Publication date: September 7, 2023
    Applicants: ONO PHARMACEUTICAL CO., LTD., NIPPON MEDICAL SCHOOL FOUNDATION
    Inventors: Atsuhiro SAKAMOTO, Tatsuaki OKAMURA, Tomohiro HARADA
  • Publication number: 20230271952
    Abstract: Disclosed are compounds of following formula (I): in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.
    Type: Application
    Filed: May 5, 2023
    Publication date: August 31, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akito KAKUUCHI, Shuhei UMEMURA, Masaki ASADA, Anatoly RUVINSKY, Yan ZHANG, Hidenori TAKAHASHI, Goran KRILOV, Daigo INOYAMA, Kyle KONZE, Mats SVENSSON
  • Publication number: 20230272079
    Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
    Type: Application
    Filed: February 9, 2023
    Publication date: August 31, 2023
    Applicants: E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.
    Inventors: Alan J. KORMAN, Mohan SRINIVASAN, Changyu WANG, Mark J. SELBY, Bingliang CHEN, Josephine M. CARDARELLI, Haichun HUANG
  • Publication number: 20230220022
    Abstract: Disclosed are a novel therapeutic means effective and practical against cancer, and a novel substance useful as such a therapeutic means. Provided are novel peptides derived from a partial region of HMGN1, HMGN2, HMGN4 or HMGN5, and anti-cancer agents and anti-cancer effect enhancers containing the peptide as an active ingredient. The peptide of the present invention has an anti-tumor effect even independently, and exerts a remarkably excellent anti-tumor effect particularly when used in combination with an immune checkpoint regulator, or an anti-CD4 antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: January 3, 2023
    Publication date: July 13, 2023
    Applicants: The University of Tokyo, ONO PHARMACEUTICAL CO., LTD., TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Kouji MATSUSHIMA, Satoshi UEHA, Shungo DESHIMARU, Chang-Yu CHEN, Shoji YOKOCHI, Yoshiro ISHIWATA, Shiro SHIBAYAMA
  • Patent number: 11691968
    Abstract: Disclosed are compounds of following formula (I): in which all symbols have the same meanings as the definitions described in the specification; or a salt thereof. The compounds or a salt thereof are useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, Alzheimer's disease and the like.
    Type: Grant
    Filed: October 24, 2022
    Date of Patent: July 4, 2023
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akito Kakuuchi, Shuhei Umemura, Masaki Asada, Anatoly Ruvinsky, Yan Zhang, Hidenori Takahashi, Goran Krilov, Daigo Inoyama, Kyle Konze, Mats Svensson
  • Publication number: 20230190698
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Application
    Filed: February 15, 2023
    Publication date: June 22, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru KAMBE, Toru MARUYAMA, Shinsaku YAMANE, Satoshi NAKAYAMA, Kousuke TANI
  • Publication number: 20230181554
    Abstract: New uses of an FF-MAS metabolism inhibitor for protecting and/or regenerating a neuromuscular junction or for treating and/or preventing a disorder of a neuromuscular junction are disclosed. In one aspect, a method for protecting and/or regenerating a neuromuscular junction or a method for treating and/or preventing a disorder of a neuromuscular junction, the method including administering an effective amount of an FF-MAS metabolism inhibitor to a mammal is disclosed. In one aspect, an FF-MAS metabolism inhibitor for use in protecting and/or regenerating a neuromuscular junction or for use in treating and/or preventing a disorder of a neuromuscular junction is disclosed. In one aspect, uses of an FF-MAS metabolism inhibitor for manufacturing an agent for protecting and/or regenerating a neuromuscular junction or for manufacturing an agent for treating and/or preventing a disorder of a neuromuscular junction are disclosed.
    Type: Application
    Filed: May 24, 2021
    Publication date: June 15, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaya NAKANISHI, Kazuo KANAYA, Fumihiko KISA, Ryosuke WATANABE, Ryo ITO
  • Publication number: 20230151024
    Abstract: The object of the present invention is to provide a drug containing a compound having an agonistic activity to STING as an active ingredient. As a result of intensive studies by the inventors of the present invention, the compound represented by the following general formula (I-1) [in the formula, all symbols represent the same meanings as described in the present specification.] or the like, having the agonistic activity to STING, as a substance capable of solving such objects, and this invention was completed. Since the compound represented by the general formula (I-1) or the like of the present invention has the agonistic activity to STING, it can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Application
    Filed: April 10, 2020
    Publication date: May 18, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
  • Publication number: 20230143066
    Abstract: A method for removing coloration from a drug substance solution of protein preparation, in particular, antibody preparation, a method for preparing drug substance solution of protein preparations including it, as a part thereof, and highly concentrated, colorless drug substance solutions thereof are disclosed. The method removes terminal glycation products causing the coloration in the drug substance solution of protein preparation, in particular, antibody preparation, by anion-exchange chromatography, making it possible to provide colorless drug substance solutions.
    Type: Application
    Filed: April 16, 2021
    Publication date: May 11, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shinya NOZAKI, Naoki ARIMA
  • Publication number: 20230141284
    Abstract: A prescription capable of avoiding induction of inflammatory cytokine production caused by a STING agonistic compound in a cancer patient, when suppressing the progression of, suppressing the recurrence of and/or treating cancer by the STING agonistic compound, is provided. A prescription that a STING agonistic compound is administered in combination with an adrenal corticosteroid when suppressing the progression of, suppressing the recurrence of and/or treating cancer. Methods for avoiding an induction of inflammatory cytokine production by administering the prescription in combination with an adrenal corticosteroid when administering a STING agonistic compound at reduced dosage in combination with an anti-neoplastic agent.
    Type: Application
    Filed: April 9, 2021
    Publication date: May 11, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhiko TAKEDA, Ryohei MIYATA, Tomoya KOIKE, Akira KATSUBE
  • Publication number: 20230138003
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Application
    Filed: December 23, 2022
    Publication date: May 4, 2023
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki TANAKA, Takashi KONDO, Yasuo HIROOKA, Taihei NISHIYAMA, Atsushi HIRAMATSU, Tomoyuki KODA, Sho KOUYAMA
  • Patent number: 11638744
    Abstract: A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer, by administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: May 2, 2023
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro Shibayama, Hiroshi Arima, Takuya Simbo